High expression of transcriptional factor HoxB9 predicts poor prognosis in patients with lung adenocarcinoma

Histopathology

Volumn 66, Issue 7, 2015, Pages 955-965

  Zhan, Jun ^a,b   Wang, Peng ^a,b   Niu, Miaomiao ^a,b   Wang, Yunling ^a,b   Zhu, Xiang ^a,c   Guo, Yongqing ^d   Zhang, Hongquan ^a,b  

^a Department of Biochemistry and Molecular BiologyCancer Hospital of Peking University   (China)

^b Department of Anatomy Histology and Embryology Laboratory of Molecular Cell Biology and Tumor Biology   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d Sino Japanese Hospital   (China)

Author keywords

HoxB9; Lung adenocarcinoma; Prognosis; Tumour marker

Indexed keywords

NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXB9; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; HOMEODOMAIN PROTEIN; HOXB9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SURVIVAL TIME; UPREGULATION; VERY ELDERLY; ADENOCARCINOMA; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; ADENOCARCINOMA OF LUNG; ADULT; AGED; BIOMARKERS, TUMOR; CELL MOVEMENT; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; UP-REGULATION;

EID: 84929086980     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12585     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61; 69-90.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 2007; 57; 43-66.
3. Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR. Htert expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin. Cancer Res. 2002; 8; 2883-2889.
4. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 2007; 356; 800-808.
5. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol. 2007; 8; 889-897.
6. Chen HY, Yu SL, Chen CH et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 2007; 356; 11-20.
7. Lau SK, Boutros PC, Pintilie M et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J. Clin. Oncol. 2007; 25; 5562-5569.
8. Kratz JR, He J, Van Den Eeden SK et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012; 379; 823-832.
9. Fan Z, Schraeder R. The changing pathology of lung cancer. Surg. Oncol. Clin. N. Am. 2011; 20; 637-653.
10. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008; 58; 71-96.
11. Bonanno L, Schiavon M, Nardo G et al. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res. 2010; 30; 5121-5128.
12. Cai G, Wong R, Chhieng D et al. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol. 2013; 121; 500-507.
13. Ryuge S, Sato Y, Jiang SX et al. The clinicopathological significance of LGR5 expression in lung adenocarcinoma. Lung Cancer 2013; 82; 143-148.
14. Zhang J, Ni SS, Zhao WL, Dong XC, Wang JL. High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma. Tumour Biol. 2013; 34; 2397-2401.
15. Yang M, Shen H, Qiu C et al. High expression of MIR-21 and MIR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur. J. Cancer 2013; 49; 604-615.
16. Corominas-Faja B, Oliveras-Ferraros C, Cuyas E et al. Stem cell-like ALDH(bright) cellular states in egfr-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle 2013; 12; 3390-3404.
17. Alamgeer M, Ganju V, Szczepny A et al. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax 2013; 68; 1095-1104.
18. Chiou SH, Wang ML, Chou YT et al. Coexpression of OCT4 and NANOG enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010; 70; 10433-10444.
19. Garcia-Fernandez J. The genesis and evolution of homeobox gene clusters. Nat. Rev. Genet. 2005; 6; 881-892.
20. Ohta H, Hamada J, Tada M et al. HOXD3-overexpression increases integrin alpha v beta 3 expression and deprives e-cadherin while it enhances cell motility in a549 cells. Clin. Exp. Metastasis 2006; 23; 381-390.
21. Kim DS, Kim MJ, Lee JY et al. Epigenetic inactivation of homeobox a5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features. Mol. Carcinog. 2009; 48; 1109-1115.
22. Kim SD, Park RY, Kim YR et al. HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression. Anat. Cell Biol. 2010; 43; 284-293.
23. Miller GJ, Miller HL, van Bokhoven A et al. Aberrant hoxc expression accompanies the malignant phenotype in human prostate. Cancer Res. 2003; 63; 5879-5888.
24. Raman V, Martensen SA, Reisman D et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 2000; 405; 974-978.
25. Sun M, Song CX, Huang H et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc. Natl Acad. Sci. USA 2013; 110; 9920-9925.
26. Kanai M, Hamada J, Takada M et al. Aberrant expressions of HOX genes in colorectal and hepatocellular carcinomas. Oncol. Rep. 2010; 23; 843-851.
27. Ghoshal K, Motiwala T, Claus R et al. HOXB13, a target of DNMT3B, is methylated at an upstream CPG island, and functions as a tumor suppressor in primary colorectal tumors. PLoS ONE 2010; 5; e10338.
28. Li B, Jin H, Yu Y et al. Hoxa10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int. J. Gynecol. Cancer 2009; 19; 1347-1352.
29. Matei DE, Nephew KP. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol. Oncol. 2010; 116; 195-201.
30. Naora H, Montz FJ, Chai CY, Roden RB. Aberrant expression of homeobox gene hoxa7 is associated with mullerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response. Proc. Natl Acad. Sci. USA 2001; 98; 15209-15214.
31. Hatzis P, van der Flier LG, van Driel MA et al. Genome-wide pattern of tcf7 l2/tcf4 chromatin occupancy in colorectal cancer cells. Mol. Cell. Biol. 2008; 28; 2732-2744.
32. Chiba N, Comaills V, Shiotani B et al. Homeobox b9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proc. Natl Acad. Sci. USA 2012; 109; 2760-2765.
33. Hayashida T, Takahashi F, Chiba N et al. Hoxb9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc. Natl Acad. Sci. USA 2010; 107; 1100-1105.
34. Sha S, Gu Y, Xu B et al. Decreased expression of hoxb9 is related to poor overall survival in patients with gastric carcinoma. Dig. Liver Dis. 2013; 45; 422-429.
35. Calvo R, West J, Franklin W et al. Altered hox and wnt7a expression in human lung cancer. Proc. Natl Acad. Sci. USA 2000; 97; 12776-12781.
36. Zhan J, Niu M, Wang P, Zhu X, Li S, Song J, He H, Wang Y, Xue L, Fang W, Zhang H. Elevated HOXB9 expression promotes differentiation and predicts a favourable outcome in colon adenocarcinoma patients. Br J Cancer 2014; 387; 1038-1050.
37. Barkauskas CE, Cronce MJ, Rackley CR et al. Type 2 alveolar cells are stem cells in adult lung. J. Clin. Invest. 2013; 123; 3025-3036.
38. Kapanci Y, Weibel ER, Kaplan HP, Robinson FR. Pathogenesis and reversibility of the pulmonary lesions of oxygen toxicity in monkeys. II. Ultrastructural and morphometric studies. Lab. Invest. 1969; 20; 101-118.
39. Rock JR, Barkauskas CE, Cronce MJ et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl Acad. Sci. USA 2011; 108; E1475-E1483.
40. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J. Clin. Oncol. 2007; 25; 561-570.
41. Travis WD. Pathology of lung cancer. Clin. Chest Med. 2011; 32; 669-692.
42. Wei L, Zhao S, Chen MY, Chen Z, Chen X. Clinical research on surgical treatment for non-small cell lung cancer of diameter less than 2 cm. Zhonghua yi xue za zhi 2013; 93; 2502-2504.
43. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J. Thorac. Oncol. 2013; 8; 612-618.
44. Nguyen DX, Chiang AC, Zhang XH et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009; 138; 51-62.